1. IL-2 and IL-1β Patient Immune Responses Are Critical Factors in SARS-CoV-2 Infection Outcomes
   Shereen Fawzy et al, 2022, Journal of Personalized Medicine CrossRef
2. In Vitro Exposure of Primary Human T Cells and Monocytes to Polyclonal Stimuli Reveals a Basal Susceptibility to Display an Impaired Cellular Immune Response and Develop Severe COVID-19
   Rebeca Viurcos-Sanabria et al, 2022, Frontiers in Immunology CrossRef
3. Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
   Amalia Anastasopoulou et al, 2022, Immunotherapy CrossRef
4. SARS-CoV-2 infection induces a long-lived pro-inflammatory transcriptional profile
   Jia-Yuan Zhang et al, 2023, Genome Medicine CrossRef
5. The role of cytokines and their antagonists in the treatment of COVID‐19 patients
   Zeinab Mohseni Afshar et al, 2023, Reviews in Medical Virology CrossRef
6. Cytokines and microRNAs in SARS-CoV-2: What do we know?
   Fahimeh Zamani Rarani et al, 2022, Molecular Therapy - Nucleic Acids CrossRef
7. Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID
   Manish Dhawan et al, 2023, Vaccines CrossRef
8. The role of Recombinant interleukin-2 in the treatment of patients with chronic hepatitis B.
   Anastasiya F. Novikova et al, 2024, Russian Journal of Infection and Immunity CrossRef
9. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)
   Lívia Pimenta Bonifácio et al, 2023, Revista da Sociedade Brasileira de Medicina Tropical CrossRef